相关临床试验
107
29 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1996
进行中（未招募）
28
26.2%
已完成
41
38.3%
尚未招募
1
0.9%
招募中
18
16.8%
终止
17
15.9%
Unknown
1
0.9%
撤回
1
0.9%
暂无批准数据
- Ireland's Minister for Further and Higher Education launched Phase 2 of Precision Oncology Ireland (POI), the country's largest cancer research program focused on personalized cancer care. - The program represents a substantial increase in investment, scale and ambition compared to Phase 1, with enhanced clinical engagement and broader scientific scope. - POI-2 aims to embed research within standard cancer care and develop advanced computer simulations to design individualized diagnostic and treatment approaches for each patient. - The initiative brings together academics, industry partners, charities, and patients in a cross-sector collaborative model coordinated by University College Dublin's Systems Biology Ireland centre.
- Greenwich LifeSciences received European regulatory approval to expand its Phase III FLAMINGO-01 clinical trial to Ireland, adding to a global network of 150 trial sites across seven countries. - The trial evaluates GLSI-100 immunotherapy in HER2-positive breast cancer patients with residual disease or high-risk pathologic complete response after surgery and trastuzumab treatment. - Ireland diagnosed 3,723 new breast cancer cases in 2022, representing 30% of all cancers in women and the second leading cause of cancer death with 883 deaths. - Dr. Janice Walshe from St Vincent's University Hospital in Dublin will serve as national principal investigator, bringing extensive experience in international breast cancer trials.
